Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Balding Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

NCT04459650
View directory record Official record
Conditions
Alopecia
Interventions
Platelet Rich Plasma system
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 16, 2026, 9:06 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

NCT07133308
View directory record Official record
Conditions
Alopecia Areata
Interventions
Deuruxolitinib, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Early Phase 1 Interventional

A Clinical Comparison of FDA-Cleared Photobiomodulation Devices for the Treatment of Alopecia

NCT06748287
View directory record Official record
Conditions
Alopecia
Interventions
iGrow Hair Growth System, Capillus352, HairMax Ultima 12 Lasercomb, HairMax Laserband 82
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 85 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health

NCT06120933
View directory record Official record
Conditions
Hair Health, Hair Loss
Interventions
Hair Nutra Growth Supplement & Hair Nutra Boost Supplement, Hair Nutra Growth
Dietary Supplement
Lead sponsor
BrandiZone
Industry
Eligibility
30 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata

NCT01797432
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10), Restylane
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

NCT03575780
View directory record Official record
Conditions
Actinic Keratoses
Interventions
KX2-391 Ointment 1%
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

NCT02275351
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
SM04554, Vehicle
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

NCT01451112
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
2
States / cities
Paramus, New Jersey • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)

NCT01451047
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

NCT03570749
View directory record Official record
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 16, 2026, 9:06 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

NCT01385839
View directory record Official record
Conditions
Alopecia Areata, Alopecia, Balding
Interventions
Hair transplantation, Hypodermic needle irritation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Sep 16, 2026, 9:06 PM EDT
Terminated Phase 4 Interventional Results available

Intralesional Steroids in the Treatment of Alopecia Areata

NCT01898806
View directory record Official record
Conditions
Alopecia Areata
Interventions
Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml, Intralesional Saline
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 16, 2026, 9:06 PM EDT
Recruiting Phase 2 Interventional

A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

NCT07533006
View directory record Official record
Conditions
Alopecia Areata
Interventions
LY4005130, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Fremont, California • Northridge, California • Santa Clarita, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

NCT00187577
View directory record Official record
Conditions
Alopecia Areata
Interventions
Latanoprost (Xalatan), Bimatoprost (Lumigan), Topical application of latanoprost solution to eyelid
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

NCT03206567
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement capsules, Placebo capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 16, 2026, 9:06 PM EDT
Recruiting Not applicable Interventional

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

NCT04764331
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Revian Red All LED cap
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

NCT02299297
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tofacitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 16, 2026, 9:06 PM EDT
Withdrawn Phase 2 Interventional

Topical Crisaborole in Patients with Alopecia Areata

NCT04299503
View directory record Official record
Conditions
Alopecia Areata
Interventions
Crisaborole Topical Ointment, Placebo Topical Ointment
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 16, 2026, 9:06 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05914805
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 16, 2026, 9:06 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428
View directory record Official record
Conditions
Alopecia Areata
Interventions
bempikibart (ADX-914)
Drug
Lead sponsor
Q32 Bio Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
28
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 16, 2026, 9:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy

NCT01967277
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Handi-Dome Laser, Incandescent red light source.
Device
Lead sponsor
Capillus, LLC
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Great Neck, New York • Woodbury, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 16, 2026, 9:06 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

NCT06482541
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling
Combination Product
Lead sponsor
Levit Dermatology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 16, 2026, 9:06 PM EDT